Publications
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Science, Faculty of Medicine in Pilsen
- Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC2017 | Faculty of Science, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | Faculty of Science, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene2016 | Faculty of Science, Faculty of Medicine in Pilsen
- Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC2016 | Faculty of Science, Faculty of Medicine in Pilsen
- Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib2016 | Faculty of Science, Faculty of Medicine in Pilsen
- Monitoring of circulating tumor cells by a combination of immunomagnetic enrichment and RT-PCR in colorectal cancer patients undergoing surgery2016 | First Faculty of Medicine
- High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib2015 | Faculty of Science, First Faculty of Medicine, Faculty of Medicine in Pilsen
- Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation2015 | Faculty of Science, Faculty of Medicine in Pilsen
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Faculty of Science, Faculty of Medicine in Pilsen, Central Library of Charles University
Loading network view...